Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma

Hao Yin, Menghan Zhang, Congying Gu, Zhenyu Li, Chenyan Hao, J. Wang, Lulu Tian, Kang Xu, Xiangyu Hu, Liqin Ming, Min Zhang, Zhanbo Wang, Yong Yang, Dayong Zhang, Beiying DaiJournal of Medicinal Chemistry 2024 · DOI

Abstract

Beta-1,3-glucuronosyltransferase (B3GAT3), overexpressed in hepatocellular carcinoma (HCC) and negatively correlated to prognosis, is a promising target for cancer therapy. Currently, no studies have reported small molecule inhibitors of B3GAT3. In this study, we designed and synthesized a series of small-molecule inhibitors of B3GAT3 through virtual screening and structure optimization. The lead compound <b>TMLB-C16</b> exhibited potent B3GAT3 inhibitory activity (KD = 3.962 μM) by effectively suppressing proliferation and migration, and inducing cell cycle arrest and apoptosis in MHCC-97H (IC<sub>50</sub>= 6.53 ± 0.18 μM) and HCCLM3 (IC<sub>50</sub>= 6.22 ± 0.23 μM) cells. Furthermore, compound <b>TMLB-C16</b> demonstrated favorable pharmacokinetic properties with a relatively high bioavailability of 68.37%. It significantly inhibited tumor growth in both MHCC-97H and HCCLM3 xenograft tumor models without causing obvious toxicity. These results indicate that compound <b>TMLB-C16</b> is an effective small molecule inhibitor of B3GAT3, providing a basis for the future development of B3GAT3-targeted drugs.
BibTeX
@article{yin2024discovery,
  author = {Hao Yin and Menghan Zhang and Congying Gu and Zhenyu Li and Chenyan Hao and J. Wang and Lulu Tian and Kang Xu and Xiangyu Hu and Liqin Ming and Min Zhang and Zhanbo Wang and Yong Yang and Dayong Zhang and Beiying Dai},
  title = {{Discovery of Novel 2-Oxoacetamide Derivatives as B3GAT3 Inhibitors for the Treatment of Hepatocellular Carcinoma}},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c00242},
}

Loading related content...

Figure